Tyrosine Kinase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
| Line 8: | Line 8: | ||
|- | |- | ||
! Parameter | ! Parameter | ||
| - | ! [[Sunitinib]] (Sutent) | + | ! [[Sunitinib]]<br/>(Sutent) |
| - | ! [[Sorafenib]] (Nexavar) | + | ! [[Sorafenib]]<br/>(Nexavar) |
| - | ! [[Erlotinib]] <br/>(Tarceva) | + | ! [[Erlotinib]]<br/>(Tarceva) |
| - | ! [[Gefitinib]] <br/>(Iressa) | + | ! [[Gefitinib]]<br/>(Iressa) |
| - | ! [[Lapatinib]] <br/>(Tykerb) | + | ! [[Lapatinib]]<br/>(Tykerb) |
|- | |- | ||
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ||
Revision as of 13:44, 9 December 2010
| Tyrosine Kinase Inhibitor Pharmacokinetics | |||||
|---|---|---|---|---|---|
| VEGFR Inhibitor Pharmacokinetics | EGFR Inhibitor Pharmacokinetics | ||||
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | Erlotinib (Tarceva) | Gefitinib (Iressa) | Lapatinib (Tykerb) |
| Tmax (hr) | 8 | 8.3 | 2.0 | 5.4 | 4 |
| Cmax (ng/ml) | 24.6 | 460 | 69.6 | 130 | 115 |
| Bioavailability (%) | Variable | 29-49 | 99 | 59 | Variable |
| Protein Binding (%) | 95 | 99 | 93 | 90 | 99 |
| T1/2 (hr) | 83 | 29 | 9.4 | 26.9 | 9.6 |
| AUC (ng/ml/hr) | 1921 | 11040 | 20577 | 3850 | 1429 |
| Dosage (mg) | 50 | 50 | 150 | 250 | 100 |
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic - (CYP3A4) | Hepatic - (CYP3A4) | Hepatic - (CYP3A4) |
For references see: References
